| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.48▲ | 1.47▲ | 1.47▲ | 1.45▲ | 1.54▼ |
| MA10 | 1.47▲ | 1.45▲ | 1.46▲ | 1.46▲ | 1.55▼ |
| MA20 | 1.45▲ | 1.46▲ | 1.45▲ | 1.51▼ | 2.06▼ |
| MA50 | 1.44▲ | 1.45▲ | 1.45▲ | 1.55▼ | 31.17▼ |
| MA100 | 1.45▲ | 1.46▲ | 1.49▲ | 2.14▼ | 23.69▼ |
| MA200 | 1.45▲ | 1.50▼ | 1.53▼ | 18.61▼ | 39.03▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | 0.006▲ | 0.006▲ | 0.003▲ | 1.519▲ |
| RSI | 71.985▲ | 61.334▲ | 58.202▲ | 46.152▼ | 36.109▼ |
| STOCH | 82.937▲ | 80.364▲ | 51.282 | 38.437 | 14.308▼ |
| WILL %R | 0.000▲ | -16.000▲ | -19.231▲ | -63.636 | -89.865▼ |
| CCI | 112.923▲ | 91.136 | 78.261 | -48.003 | -78.036 |
|
Thursday, November 06, 2025 07:07 AM
Aptevo Therapeutics Inc. (NASDAQ:APVO) shares were unchanged first thing Thursday. The Seattle-based company, a clinical-stage biotechnology concern focused on developing novel immune-oncology ...
|
|
Thursday, November 06, 2025 05:15 AM
AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 07/11/25 | 1.41 | 1.50 | 1.39 | 1.47 | 1,213,785 |
| 06/11/25 | 1.42 | 1.53 | 1.41 | 1.47 | 759,759 |
| 05/11/25 | 1.43 | 1.44 | 1.395 | 1.43 | 475,321 |
| 04/11/25 | 1.42 | 1.50 | 1.40 | 1.41 | 607,189 |
| 03/11/25 | 1.53 | 1.53 | 1.45 | 1.47 | 773,743 |
| 31/10/25 | 1.42 | 1.58 | 1.39 | 1.55 | 1,887,655 |
| 30/10/25 | 1.40 | 1.42 | 1.40 | 1.40 | 446,313 |
| 29/10/25 | 1.47 | 1.4705 | 1.41 | 1.42 | 744,599 |
| 28/10/25 | 1.50 | 1.50 | 1.46 | 1.46 | 725,393 |
| 27/10/25 | 1.51 | 1.54 | 1.50 | 1.50 | 572,206 |
|
|
||||
|
|
||||
|
|